Firm
Tilleke & Gibbins topped the leaderboard with four awards across the region, while Anand & Anand and Kim & Chang emerged as outstanding domestic firms
News of a new addition to Via LA’s Qi wireless charging patent pool, and potential fee increases at the UKIPO were also among the top talking points
The keenly awaited ruling should act as a ‘call to arms’ for a much-needed evolution of UK copyright law, says Rebecca Newman at Addleshaw Goddard
The court ordering a complainant to rank its arguments in order of potential success and a win for Edwards Lifesciences were among the top developments in recent weeks
Sponsored
Sponsored
-
Sponsored by Anand and AnandAchuthan Sreekumar of Anand and Anand draws on a recent High Court of Delhi ruling on the unauthorised use of Ratan Tata’s identity to consider how Indian jurisprudence protects well-known personal names -
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Chenxi Cui of Tahota Law Firm draw on the case and several other legal disputes to explore the fractious relationship between games console emulators and manufacturers
-
Sponsored by Liu, Shen & AssociatesJun Qiu of Liu, Shen & Associates analyses two recent CNIPA decisions that provide insights into the application of the good faith principle in patent re-examination and invalidation procedures in China
-
Sponsored by TOPPAN Digital IPThe team at TOPPAN Digital IP believe there are key flaws in current intellectual property systems and services. Managing IP hears how the company’s STREAM IP platform is aimed at addressing them
-
Sponsored by Liu, Shen & AssociatesDongguo Liang of Liu, Shen & Associates says DeepSeek should take swift action to address ‘insufficient planning’ in its intellectual property protection strategy and an ‘underdeveloped’ patent portfolio
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China
